All GLP-1 medications from licensed 503A compounding pharmacies Browse Products

Originally posted by @koakley2024 on TikTok ยท 82s|Watch on TikTok
Full video transcriptClick to expand

Auto-generated transcript of @koakley2024's video. Quoted here for educational fact-check commentary; original creator retains all rights to the video content.

  1. 0:00So let's do a quick three months check up on my weight loss progress because I checked my medical records out and
  2. 0:07There's a cool graph. So I'm gonna move myself down here
  3. 0:10So up here is a graph and that top weight there
  4. 0:16Was 145 back in August and I was weighed 319.67 pounds
  5. 0:21So I was actually a little bit higher before I even started my weight loss journey, right?
  6. 0:24So crazy, but now we're gonna go back to the graph
  7. 0:28That's from August all the way until December. So now we're it's 10 or so three and a half four months and
  8. 0:35This is gonna be my wrist. This was my doctor's appointment a couple days ago
  9. 0:39So that means I have went from 319 pounds as a starting weight before the tres appetite. I am now down to 282
  10. 0:48So does that oh nine ninety nine eighty nine?
  11. 0:51That's a 37 pound weight loss
  12. 0:56So my scale at home is a little off
  13. 0:59But crazy
  14. 1:01This is crazy because that was my starting weight and that was more like three so
  15. 1:06I'm like four or five pounds under what the doctors are reading it out, but that is so
  16. 1:12insane to me
  17. 1:14that progress
  18. 1:16Well
  19. 1:17Let's keep rolling y'all this is insane. I love it

Tirzepatide 3-month weight loss progress: what the data says

Gilly ๐Ÿ˜Ž

TikTok creator

1.9K viewsWatch on TikTok โ†’

Quick answer

The creator documents a 37-pound weight loss (approximately 11.6% of starting body weight) over roughly 16 weeks on tirzepatide (Zepbound), citing medical records from a clinical visit. This rate of loss is consistent with early-phase outcomes reported in the SURMOUNT-1 trial, where tirzepatide produced significant weight reduction during the initial dose-escalation period. No adverse effects, dosing information, or medication changes are discussed in the video.

Video review standard

Clinical fact-check snapshot

FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.

GLP-1 social video fact-checksCompounded TirzepatideProvider discussion

Evidence signal

Source-backed review

Regulatory reality

Compounded Tirzepatide access requires the right clinical path

Safety screen

Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.

This page currently connects to 7 source-backed evidence items through visible references or structured citation data.

PubMed evidence trail

Research sources used to frame this page

For Tirzepatide 3-month weight loss progress: what the data says, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.

Provider decision path

Use local research to choose a safer review path

Direct answer

Compounded Tirzepatide is best used to compare access, oversight, pricing, pharmacy quality, and patient support before starting care.

Evidence check

Directory pages should connect local intent with provider standards, pharmacy transparency, and practical next steps.

Safety check

Provider quality, pharmacy source, prescribing model, and follow-up support can matter as much as the medication name.

Next step

When you are ready, the get-started flow can collect the details needed for a prescription review instead of leaving you to guess.

Claim path

Keep researching this tirzepatide video claims cluster

Best for searchers deciding whether tirzepatide claims are stronger, safer, or more relevant than semaglutide claims.

Page-specific review note

What this exact clip is really saying

This FormBlends review is specific to "Tirzepatide 3-month weight loss progress: what the data says" from Gilly ๐Ÿ˜Ž. We read the clip as a GLP-1 social video fact-checks claim about Compounded Tirzepatide, then separate the useful signal from what a short social video cannot prove. The page-specific claim focus is: The creator documents a 37-pound weight loss (approximately 11.

The reason this review is not generic is the source wording and the canonical claim label "glp1 my zepbound tirzepatide weight loss progress according to my." In this clip, the useful excerpt is: "So let's do a quick three months check up on my weight loss progress because I checked my medical records out and There's a cool graph." That wording changes the review because it points to Compounded Tirzepatide safety, access, evidence, and fit, not a one-size-fits-all protocol.

The source trail for this page is checked against Once-Weekly Semaglutide in Adults with Overweight or Obesity (2021), Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance (2021), and Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight (2022), plus the creator's own wording. Compounded Tirzepatide still needs an eligibility review, medication-interaction screen, access check, and quality-control review before anyone treats a social clip as medical advice.

A 37-pound loss from 319 pounds represents about 11.
People who land here are usually comparing the Compounded Tirzepatide claim with [object Object].
The strongest next step is to compare the claim with FormBlends' Compounded Tirzepatide guide, evidence notes, and provider review path before acting.

Claim verdict

The useful answer behind this video

This page is built to answer the specific claim behind the clip, then separate what is useful from what still needs clinical context. That makes the URL more than a repost: it gives Google, readers, and AI retrieval systems a concise verdict with source and safety boundaries.

Claim being checked

The creator documents a 37-pound weight loss (approximately 11.

FormBlends verdict

Compounded Tirzepatide safety, access, evidence, and fit

Evidence strength

Source-backed review with clinical or regulatory citations.

Patient-safe next step

Compare the claim with the Compounded Tirzepatide guide, safety notes, access rules, and a licensed-provider review.

What to do with this video

Use the clip as a claim to verify, not a treatment plan

What it helps with

  • The creator documents a 37-pound weight loss (approximately 11.6% of starting body weight) over roughly 16 weeks on tirzepatide (Zepbound), citing medical records from a clinical visit. This rate of loss is consistent with early-phase outcomes reported in the SURMOUNT-1 trial, where tirzepatide produced significant weight reduction during the initial dose-escalation period. No adverse effects, dosing information, or medication changes are discussed in the video.
  • SURMOUNT-1 (Jastreboff et al., 2022, NEJM) showed average weight loss of 20.9% over 72 weeks on 15 mg tirzepatide, meaning strong early results like this are expected for some patients but not guaranteed for all.
  • A 37-pound loss from 319 pounds represents about 11.6% of starting body weight over 16 weeks, which falls within the range of documented early-phase outcomes in tirzepatide trials.

What it may miss

  • It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
  • Compounded Tirzepatide decisions still need source quality, legal access, and provider oversight checks.
  • Social video captions rarely show the full evidence base behind a claim.

Best next step

Compare the claim against the Compounded Tirzepatide guide, cost path, safety notes, and provider review before acting.

Review Compounded Tirzepatide

What You'll Learn

  • SURMOUNT-1 (Jastreboff et al., 2022, NEJM) showed average weight loss of 20.9% over 72 weeks on 15 mg tirzepatide, meaning strong early results like this are expected for some patients but not guaranteed for all.
  • A 37-pound loss from 319 pounds represents about 11.6% of starting body weight over 16 weeks, which falls within the range of documented early-phase outcomes in tirzepatide trials.
  • Tirzepatide acts on both GIP and GLP-1 receptors, a dual mechanism that Frias et al. (2023, Diabetes Care) found produces faster initial weight loss compared to GLP-1 monotherapy like semaglutide.
  • The steepest weight loss on GLP-1 and GIP/GLP-1 agonists typically occurs during the early dose-escalation phase; the rate of loss usually slows as the body adapts and a new metabolic set point is approached.
  • Home scales commonly read 2-6 pounds lower than calibrated clinic scales due to clothing, time of day, and device calibration differences. Always use the same measurement conditions when tracking your own progress.
  • Individual results on tirzepatide vary widely even under controlled trial conditions. Comparing personal progress to someone else's TikTok timeline is not clinically meaningful.
  • Tirzepatide is a prescription medication requiring medical supervision. Dose titration, lab monitoring, and ongoing evaluation by a licensed prescriber are part of safe and effective use.

Our take ยท Written by FormBlends editorial team ยท Reviewed by FormBlends Medical Team ยท This is not a transcript. It is our independent review of the video above.

What did @koakley2024 actually say?

Pretty straightforward: this creator shared their medical records showing a weight drop from 319.67 pounds down to 282 pounds over roughly three and a half to four months on tirzepatide (Zepbound). That works out to a 37-pound loss, which they called "insane" progress. They also noted their home scale reads about four to five pounds lighter than the clinic scale, which is a real and common discrepancy worth flagging.

No wild claims here. No promises of a cure, no specific dose recommendations, no before-and-after photo manipulation. Just someone reading a graph from their actual medical record and doing the math out loud. The transparency is refreshing compared to a lot of GLP-1 content on TikTok.

Does the science back this up?

Yes, and then some. A 37-pound loss over roughly 16 weeks is aggressive but entirely consistent with what clinical trials have shown for tirzepatide at higher doses.

The SURMOUNT-1 trial (Jastreboff et al., 2022, New England Journal of Medicine) is the key reference here. In that study, participants on 15 mg tirzepatide lost an average of 20.9% of body weight over 72 weeks. Early responders in those trials can see substantial losses in the first few months, particularly during dose escalation when appetite suppression tends to be strongest.

For someone starting at 319 pounds, a 37-pound loss represents about 11.6% of starting body weight over four months. That tracks with real-world data. A 2023 analysis by Frias et al. in Diabetes Care found that tirzepatide's dual GIP and GLP-1 receptor agonism produces faster early weight loss compared to semaglutide monotherapy, which helps explain why results in the first three to four months can look dramatic.

So the numbers are not exaggerated. If anything, they are representative of what a good early responder looks like on this medication.

What did they get wrong (or right)?

They got the core claim right. The weight loss figure appears to come directly from a medical record, which is about as credible a source as a patient can cite. No embellishment detected.

The one thing worth addressing: they mention their "starting weight before the tres appetite," which is clearly a speech-recognition or informal shorthand for tirzepatide. The implication is that 319.67 was their weight at the time they started the drug. But they also note they were "a little bit higher before" that reading. This matters because the starting point affects how you calculate total percentage loss. If their true pre-treatment peak was above 319, the percentage loss could be slightly lower than it appears on that graph.

That is a minor point, not a deception. But if you are comparing your own progress to theirs, use your own documented start weight, not a retrospective estimate.

What they got right: acknowledging the home-scale discrepancy. Clinic scales are typically calibrated and measured under controlled conditions (shoes off, consistent time of day). Home scales vary. Pointing that out without trying to game the numbers is honest.

What should you actually know?

This video is a personal progress update, not a clinical recommendation, and that distinction matters.

Individual results on tirzepatide vary significantly based on starting dose, titration schedule, diet, activity level, and metabolic factors that no TikTok video can account for. The SURMOUNT-1 trial showed a wide range of outcomes even under controlled conditions. Some participants lost over 25% of body weight; others lost closer to 5%. Comparing your month three to someone else's month three is not a useful exercise.

There is also the question of what happens after the early rapid-loss phase. Weight loss typically slows as the body adapts and as patients approach a new set point. The first four months on tirzepatide often produce the steepest part of the curve. That does not mean progress stops, but it does mean the 37-pound-in-four-months pace is unlikely to continue indefinitely.

If you are considering tirzepatide or are already on it, the right benchmark is your own medical record, not a TikTok graph. Work with a licensed prescriber who can monitor your labs, adjust dosing appropriately, and track progress over time.

Interested in GLP-1 or peptide therapy?

Get matched with licensed-provider review to help decide if it is right for you.

Free Assessment

About the Creator

Gilly ๐Ÿ˜Ž ยท TikTok creator

1.9K views on this video

My zepbound (tirzepatide) weight loss progress according to my medical record Month 3 ๐Ÿ˜Œ #greenscreenvideo #tirzepatide #tirzepatideweightloss #weightloss #weightlossjourney #zepbound #zepboundjourney #3monthprogress #makingprogress

Frequently asked questions

Quick answers based on this video and our medical team review.

What does the video say about surmount-1 (jastreboff et al., 2022, nejm) showed average weight loss?

SURMOUNT-1 (Jastreboff et al., 2022, NEJM) showed average weight loss of 20.9% over 72 weeks on 15 mg tirzepatide, meaning strong early results like this are expected for some patients but not guaranteed for all.

What does the video say about a 37-pound loss from 319 pounds represents about 11.6% of?

A 37-pound loss from 319 pounds represents about 11.6% of starting body weight over 16 weeks, which falls within the range of documented early-phase outcomes in tirzepatide trials.

What does the video say about tirzepatide acts on both gip?

Tirzepatide acts on both GIP and GLP-1 receptors, a dual mechanism that Frias et al. (2023, Diabetes Care) found produces faster initial weight loss compared to GLP-1 monotherapy like semaglutide.

What does the video say about the steepest weight loss on glp-1?

The steepest weight loss on GLP-1 and GIP/GLP-1 agonists typically occurs during the early dose-escalation phase; the rate of loss usually slows as the body adapts and a new metabolic set point is approached.

What does the video say about home scales commonly read 2-6 pounds lower than calibrated clinic?

Home scales commonly read 2-6 pounds lower than calibrated clinic scales due to clothing, time of day, and device calibration differences. Always use the same measurement conditions when tracking your own progress.

What does the video say about individual results on tirzepatide vary widely even under controlled trial?

Individual results on tirzepatide vary widely even under controlled trial conditions. Comparing personal progress to someone else's TikTok timeline is not clinically meaningful.

Sources & references

Citations extracted from our medical team's review. Click any citation to search PubMed.

Educational use only. This fact-check is editorial content for general information. Nothing here is medical advice. Talk to a licensed provider about your specific situation before starting, stopping, or changing any supplement, peptide, or medication regimen.

Read More on This Topic

Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.

Not medical advice. This video was made by Gilly ๐Ÿ˜Ž, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.